ClinicalTrials.gg
CompletedNCT00002300Updated Oct 2, 2007

A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition

A Phase 2 interventional study of Megestrol acetate in Anorexia, Cachexia and HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-10-02.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Megestrol Acetate in Anorexia — 1 open to participants now, 1 under way, none of them phase 3. Megestrol Acetate · Anorexia.

Phase 2
5 of 12
1 open now
Registered
1st of 12
by date
Lead sponsor
3 of 12
Bristol-Myers Squibb

Among the 12 studies testing Megestrol Acetate in Anorexia, this one is one of 5 in phase 2, and was the 1st registered.

Anorexia

163 studies on the registry are indexed under Anorexia; 25 are open to participants now.

Browse Anorexia studies →

Open to participants now

1 of the 12 studies testing Megestrol Acetate in Anorexia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Megestrol Acetate

Megestrol Acetate: first FDA approval 1971 (MEGACE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 12 Anorexia studies recruiting now, 6 (50%) set no upper age limit and 6 (50%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing Megestrol Acetate in Anorexia, or all of them as a file.
02

Study summary

To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To characterize dose response in relation to weight gain. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.

03

Conditions studied

  • Anorexia
  • Cachexia
  • HIV Infections

Keywords

  • T-Lymphocytes
  • Megestrol
  • Dose-Response Relationship, Drug
  • Acquired Immunodeficiency Syndrome
  • Anorexia
  • Cachexia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient must have:

  • Confirmed diagnosis of AIDS (CDC definition).
  • Documented weight loss or anorexia.
  • = or > 20 weeks.
  • The perception that the weight loss is a detriment to their well-being.
  • Ability to provide , read and write English.

Prior Medication:

Allowed:

  • Ganciclovir.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Dementia or evidence of mental incompetence which would preclude compliance with the protocol.
  • Diarrhea defined as 5 or more watery stools per day for at least 7 days.
  • Active uncontrolled systemic infections at the start of treatment.
  • (Patients may not be entered for at least 2 weeks after acute infection.) Clinical or radiologic evidence of ascites or pleural effusions.

Concurrent Medication:

Excluded:

  • Therapy designed to treat the underlying infection or which may have a major impact on appetite and/or weight gain.
  • Patients who have been started on zidovudine (AZT) within eight weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.)

Patients with the following are excluded:

  • Obstruction to food intake or impaired digestive/absorptive functions.
  • to high-dose megestrol acetate (poorly controlled hypertension or heart failure or deep vein thrombosis).
  • Inability to consent or be available for close follow-up.
  • Active systemic infections at the start of treatment.
  • Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain.
  • Clinical or radiologic evidence of ascites or pleural effusions.
  • Patients may not be started on any therapy designed to treat the underlying HIV infection or which may have a major impact on appetite and/or weight gain.
  • Patients who have been hospitalized or have suffered an exacerbation of their illness associated with weight loss within the past 2 weeks are excluded.
  • Menstruating female patients are excluded.

Prior Medication:

Excluded:

  • .
  • Anabolic steroids.
  • Marijuana.
  • Megestrol acetate.
  • Patients who have been started on zidovudine (AZT) within 8 weeks. (Patients may have been previously treated with AZT and failed or may currently be receiving AZT for at least 8 weeks.) History of substance abuse and questionable current and future abstinence.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

15 sites
  • Birmingham Veterans Administration Med Ctr / Univ of Alabama
    Birmingham, Alabama 35233, United States
  • Dr NS Tchekmedyian
    Long Beach, California 90801, United States
  • Dr Stephen J Gabin Jr
    Los Angeles, California 90067, United States
  • Eisenhower Med Ctr
    Rancho Mirage, California 92270, United States
  • Denver Public Health Dept
    Denver, Colorado 80204, United States
  • George Washington Univ Med Ctr
    Washington, District of Columbia 20037, United States
  • Veterans Administration Med Ctr
    Washington, District of Columbia 20422, United States
  • Miami Veterans Administration Med Ctr
    Miami, Florida 33125, United States
  • Northwestern Univ Med School
    Chicago, Illinois 60611, United States
  • Albany Med College / AIDS Treatment Ctr
    Albany, New York 12203, United States
  • Community Research Initiative on AIDS
    New York, New York 10010, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • Mem Sloan - Kettering Cancer Ctr
    New York, New York 10021, United States
  • Univ of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Audie L Murphy Veterans Administration Hosp
    San Antonio, Texas 78284, United States
07

References and documents

Publications

  • Strang P. The effect of megestrol acetate on anorexia, weight loss and cachexia in cancer and AIDS patients (review). Anticancer Res. 1997 Jan-Feb;17(1B):657-62. PubMed 9066597 ↗
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 2, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00002300
First posted
Aug 31, 2001
Last update
Oct 2, 2007
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion